Guerbet (GBT.PA)

Executive Summary

Guerbet, a century-old French pioneer and global leader in medical imaging contrast media, continues to leverage its deep expertise in chemistry and formulation to deliver innovative diagnostic solutions. The company's pipeline includes several late-stage assets: Gadopiclenol, a next-generation macrocyclic gadolinium-based contrast agent (GBCA) for MRI, which recently completed Phase 3 trials for detecting CNS and body lesions, supporting potential regulatory submissions; and Idarubicin combined with Lipiodol, currently in Phase 2 for hepatocellular carcinoma, with completion expected in mid-2026. Additionally, P03277, a novel MRI agent, has completed Phase 2 studies for CNS indications. Guerbet's established product portfolio, including Dotarem and Xenetix, provides a stable revenue base. The company is well-positioned to benefit from growing demand for safer, high-performance contrast agents, driven by increasing MRI and CT procedure volumes globally. With a strong focus on R&D and a century of market presence, Guerbet is poised to maintain its competitive edge in diagnostic imaging.

Upcoming Catalysts (preview)

• Q4 2026Gadopiclenol Phase 3 Data Unveiled and Regulatory Filing80% success
• Q2 2026Idarubicin + Lipiodol Phase 2 Top-Line Results for Hepatocellular Carcinoma70% success
• Q3 2026P03277 Phase 2 Data Review and Potential Next-Stage Development50% success